Contact This Organization

Nanodropper, Inc

Combating waste and rising prices in our healthcare system, Nanodropper is disrupting the ophthalmic pharmaceutical market. We are committed to offering value-based solutions to close health equity gaps while promoting patient education and advocacy. Named after our flagship product, Nanodropper has developed a patient-centered adaptor for eyedrop bottles to reduce the volume of currently oversized drops, minimizing the cost, waste, and side effects of vision-saving treatments.
Mission/Vision
Small Drops with a Big Vision: to combat health inequity through innovation
Type of Organization
Startup - Newly established businesses, investable
Vendor - i.e. Established companies, non-startup
Size of Organization
0-10
Organization Mailing Address

442 51st Ave NW
Rochester , 55901
United States

Nanodropper
The Nanodropper is a universal adaptor for eyedrop medication bottles that creates smaller and more efficacious droplets to extend bottle-life, decrease cost, and ultimately increase access to expensive medications. It offers cost-savings of up to $2500/year/Rx, eliminates premature bottle exhaustion, and reduces side effects. These benefits extend to every step in the healthcare system, reducing the burden from hospitalizations and complications due to disease progression.
Category of Innovation
Life Sciences - Life science solutions are those solutions that are delivered as a drug or device that typically require federal approval
Intended End User
Patient - Individuals who receive health care
Provider - Individuals or organizations responsible for providing care to patients (e.g. doctors, nurses, hospital/clinic administrators, etc.)
Payer - Organizations responsible for issuing or administering payment for the care received by a population of people (e.g. insurance companies)
Purchaser - Organizations responsible for purchasing health benefits for a population of people (e.g. employers or government entities)
Non-Profit/Community-Based Organization
Impactful Innovation Stage (Click Here for Details)
Adoption
Problem (i.e. barrier, issue, complication, etc.) being solved for the end user
Current eyedrop bottles waste medication by producing oversized drops that are up to 5 times the capacity of the human eye. This well documented problem in the optometry and ophthalmology disciplines poses a financial barrier-to-care for patients with high-end medications like those for glaucoma, which can cost up to $500 per bottle. Even with insurance, 25% of patients chronically run out of their drops before their next refill will be covered. Additionally, these drops are overdosing the eye, causing higher rates of serious complications and side-effects.
Idea/solution to the problem, if applicable
The Nanodropper is a universal adaptor for eyedrop medication bottles that creates smaller and more efficacious droplets to extend bottle-life, decrease cost, and ultimately increase access to expensive medications. It offers cost-savings of up to $2500/year/Rx, eliminates premature bottle exhaustion, and reduces side effects. These benefits extend to every step in the healthcare system, reducing the burden from hospitalizations and complications due to disease progression.
Level of adoption (i.e. list of customers/users, testimonials, etc.), if applicable
Since the early stages of development, the Nanodropper team has formed and strengthened relationships with pateints, eye health providers, and institutional partners across the world. After opening for presale in January 2020, the team saw those early relationships convert to supporting customers. Since beginning to ship product in June, we have delivered Nanodroppers to patients, eyecare clinics, and veterinary clinics accross the US. Some of our most notable partners include Kaiser Permanente, Seattle Childrens Hospital, and the US Air Force.
Impact (i.e. measurable outcomes), if applicable
The Nanodropper has been shown to reduce eyedrop volume by an average of 76% per drop (42uL to 10.2uL). This reduction in droplet volume extends bottle-life by up to 4x by increasing the number of effecacious doses per bottle. By extending bottle-life, we will be saving an average of $2,500/yr/Rx ultimately reducing the US expenditure on eyedrop medications by more than $2B.

From a medical standpoint, the Nanodropper team is planning to replicate the decades of clinical data showing that smaller eyedrop volumes are safer and more efficacious than their larger countreparts. We are organizing a non-inferiority trial with Eye Institute at Harborview Medical Center to take place later this year. Additionally, we have been awarded a Phase II contract with the US Air Force to trial the Nanodropper with an active duty Airmen population.
Funding Stage
Grant funded
Seed
List of Funding Sources (if applicable)
Notable Grants and Awards:
US Air Force - AFWERX Open Topic SBIR, Phase II Contract
VentureWell E-team Stage I grantee
NSF I-Corps Stage I grantee
MN DEED Launch Innovation Grant
UW Jones+Foster Accelerator
UW Holloman Health Innovation Challenge
Unite for Sight Global Health Innovation Challenge

Investment:
F&F Round (closed, private investors)
Pre-Seed Round (closed, private investors)
Seed Round (open, private and professional investors)


Certifications?
Yes
FDA Class I, HIPAA